The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.102%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,960.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

1 Oct 2020 11:01

RNS Number : 8056A
Hikma Pharmaceuticals Plc
01 October 2020
 

Hikma Pharmaceuticals PLC

 

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

 

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 87,700 ordinary shares of 10 pence

 

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 30,198 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

MIP: 1,519,989 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

MIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

MIP: 380,293 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

MIP: 1,139,696 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 1 October 2020

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From: 1 April 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

EIP: 1,102,558 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EIP: 590,134 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

EIP: 512,424 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUPGUUUUPUGUG
Date   Source Headline
17th May 20194:09 pmRNSResult of AGM
17th May 20193:33 pmRNSDirector/PDMR Shareholding
17th May 20197:00 amRNSTrading Statement
2nd May 20197:00 amRNSTotal Voting Rights
1st May 20199:00 amRNSHikma launches 100th injectable medicine in US
15th Apr 20194:26 pmRNSDirector/PDMR Shareholding
15th Apr 201912:23 pmRNSAnnual Financial Report
1st Apr 20195:42 pmRNSTotal Voting Rights
1st Apr 20195:11 pmRNSBlock listing Interim Review
18th Mar 20193:09 pmRNSDirector/PDMR Shareholding
15th Mar 201910:32 amRNSDirector/PDMR Shareholding
14th Mar 20199:14 amRNSDirector/PDMR Shareholding
13th Mar 20191:50 pmRNSDirector/PDMR Shareholding
13th Mar 20191:49 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSFinal Results
12th Mar 20197:00 amRNSDirectorate Change
1st Mar 20194:51 pmRNSTotal Voting Rights
28th Feb 20199:00 amRNSHikma establishes partnership with Melinta in MENA
27th Feb 20191:26 pmRNSBlock listing Interim Review
26th Feb 201911:08 amRNSNotice of Results
11th Feb 201910:11 amRNSDirector/PDMR Shareholding
1st Feb 20193:43 pmRNSTotal Voting Rights
29th Jan 20199:00 amRNSHikma launches Mitomycin for Injection
3rd Jan 20199:00 amRNSHikma announces agreement with Sciecure Pharma
19th Dec 20186:30 pmRNSShire
10th Dec 20189:00 amRNSHikma launches Clobazam
3rd Dec 201810:30 amRNSTotal Voting Rights
27th Nov 20189:00 amRNSHikma announces injectable licensing agreement
19th Nov 20189:00 amRNSHikma launches Triazolam Tablets
13th Nov 201811:15 amRNSHolding(s) in Company
8th Nov 20189:44 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSTrading Statement
1st Nov 201812:39 pmRNSTotal Voting Rights
16th Oct 20184:30 pmRNSBlock listing Interim Review
1st Oct 201810:53 amRNSTotal Voting Rights
1st Oct 201810:23 amRNSHolding(s) in Company
3rd Sep 201811:05 amRNSTotal Voting Rights
30th Aug 20189:58 amRNSHolding(s) in Company
28th Aug 201812:45 pmRNSHolding(s) in Company
22nd Aug 20189:41 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSHalf-year Report
23rd Jul 20189:00 amRNSNotice of Results
9th Jul 20189:00 amRNSHikma enters licensing partnership with Perrigo
2nd Jul 20184:56 pmRNSTotal Voting Rights
15th Jun 20183:24 pmRNSDirector/PDMR Shareholding
8th Jun 201811:50 amRNSDirector/PDMR Shareholding
4th Jun 201810:29 amRNSDirector/PDMR Shareholding
4th Jun 20189:00 amRNSHikma appoints Chief Transformation Officer
1st Jun 201811:34 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.